Another review on triple negative breast cancer: Are we on the right way towards the exit from the labyrinth?
The breast, Dec 2013, Vol. 22(6), p.1026-33.
Chiorean, R., et al.
http://www.thebreastonline.com/article/S0960-9776(13)00241-5/abstract?rss=yes
Triple negative breast cancer is a heterogeneous group of tumors, lacking the expression of estrogen, progesterone and HER-2 receptors. As frequency, it accounts about 15–20% of all breast cancers. Although in the last years there was a “boom” in publishing over this issue, multiple molecular classifications being elaborated, “the triple negative breast cancer odyssey ” is still far away from ending, as the complicated molecular pathways of pathogenesis and drug resistance mechanisms remain yet insufficiently explored.
